search
Back to results

Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries

Primary Purpose

Spinal Cord Injuries, Upper Extremity Paresis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active Vagus Nerve Stimulation
Placebo Vagus Nerve Stimulation
Sponsored by
Baylor Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Spinal Cord Injuries focused on measuring Vagus Nerve Stimulation (VNS), Rehabilitation, Targeted Plasticity Therapy

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Adult, aged 18-64
  • In good general health as evidenced by medical history and diagnosed with first time cervical spinal cord injury resulting in an ASIA grade B, C, or D, and level 1 or better motor function as described by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).
  • SCI caused by trauma that occurred ≥ 12 months prior to enrollment
  • Meets all clinical criteria for the surgical VNS implantation as determined by the PI, surgeon, and anesthesiologist
  • Must demonstrate some residual upper limb and hand movement in either arm
  • Appropriate candidate for VNS implantation
  • Willing and able to comply with the study protocol

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Spinal cord injuries by sharp objects, firearms, and non-traumatic or congenital causes, even if at different levels of the spinal cord
  • Participants with prior right-sided anterior cervical surgery will require laryngoscopy prior to randomization. Those with evidence of recurrent laryngeal nerve injury will be excluded.
  • Participants with prior left sided anterior cervical surgery will be eligible, regardless of prior recurrent laryngeal nerve injury. However, if at surgery there is too much scar tissue for safe implantation the surgery will be abandoned to ensure participant safety
  • Concomitant clinically significant brain injuries
  • Prior injury to vagus nerve
  • Prior or current treatment with vagus nerve stimulation
  • Participant receiving any therapy (medication or otherwise) that would interfere with VNS
  • Pregnancy or lactation
  • Clinical complications that hinder or contraindicate the surgical procedure
  • Psychiatric disorders, psychosocial, and/or cognitive impairment that would interfere with study participation, as assessed by medical evaluation
  • Abusive use of alcohol and/or illegal substances use
  • Participation in other interventional clinical trial
  • Participants with known immunodeficiency including participants who are receiving or have received chronic corticosteroids, immunosuppressants, immunostimulating agents or radiation therapy within 6 months
  • Participants with significant comorbidities or conditions associated with high risk for surgical or anesthetic survival (e.g. renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.).
  • Participants with active neoplastic disease.
  • Participants with significant local circulatory problems, (e.g. thrombophlebitis and lymphedema, and clinically-significant hypotension or bradycardia).
  • Participants with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator.
  • Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance.
  • Aphasia and other cognitive deficits may be present but participants will be excluded if are unable to understand the potential risks and benefits of the study or personally provide informed consent.
  • A recent history of syncope
  • A recent history of dysphagia
  • Currently require, or are likely to require diathermy
  • Significant respiratory issues that would interfere with participation
  • Non-English speaking
  • Patients who are acutely suicidal and/or have been admitted for a suicide attempt
  • Incarceration or legal detention

Sites / Locations

  • Baylor University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Immediate Start Vagus Nerve Stimulation group

Delayed Start Vagus Nerve Stimulation group

Arm Description

The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.

The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.

Outcomes

Primary Outcome Measures

Incidence of Adverse Events [Device Safety]
Review of adverse events reported throughout the trial will be used to inform the potential risks associated with the ReStore system and provide a better understanding of risk/benefit analysis.

Secondary Outcome Measures

Restore System Feasibility during Rehabilitation
If stimulation delivery is successful during the active portion of therapy sessions then the system is feasible to use. The primary endpoint will be: greater than 50% of the valid attempts to stimulate are successful per the ReStore system log.
Quantitative Force and Range of Motion Assessment
This is a physical assessment of upper limb changes in force/torque as a result of VNS paired rehabilitation. The primary endpoints will be: 10% increase in finger pinch and flexion force following active VNS, 10% increase in wrist flexion and extension force following active VNS, and 10% increase in wrist pronation and supination force following active VNS. This will serve as an efficacy measurement to use as basis for estimate of sample size for a pivotal trial.
Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP)
Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) is a measure used for spinal cord injury patients. The measure includes five subsets of questions designed to quantitatively measure clinical upper limb impairment (Kalsi-Ryan et al., 2012). The primary endpoint will be: >4 point shift in GRASSP assessment following active VNS. This will serve as an efficacy measurement to use as basis for estimate of sample size for a pivotal trial.

Full Information

First Posted
November 13, 2019
Last Updated
September 12, 2023
Sponsor
Baylor Research Institute
Collaborators
Wings for Life, Defense Advanced Research Projects Agency, The University of Texas at Dallas, University of Texas Southwestern Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04288245
Brief Title
Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries
Official Title
Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 15, 2021 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
April 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baylor Research Institute
Collaborators
Wings for Life, Defense Advanced Research Projects Agency, The University of Texas at Dallas, University of Texas Southwestern Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Texas Biomedical Device Center at UT Dallas has developed an innovative strategy to enhance recovery of motor and sensory function after neurological injury termed targeted plasticity therapy (TPT). This technique uses brief pulses of vagus nerve stimulation to engage pro-plasticity neuromodulatory circuits during rehabilitation exercises. Recovery is associated with neural plasticity in spared motor networks in the brain and spinal cord. Moreover, an early feasibility study and an independent, double-blind, placebo-controlled study in chronic stroke participants indicate that VNS is safe in participants with upper limb deficits, and yields a clinically-significant three-fold increase in neural connections during rehabilitation exercises. Given the track record of safety and potential for VNS to enhance recovery of upper limb motor function in spinal cord injured individuals, the purpose of this double blind randomized placebo controlled optional open-label extension study is to assess the safety of using a new device to deliver vagus nerve stimulation to reduce symptom severity in participants with SCI. Additionally, the study will assess the prospective benefit of the system and garner an initial estimate of efficacy for a subsequent trial. Participants may undergo additional sessions of training with VNS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Upper Extremity Paresis
Keywords
Vagus Nerve Stimulation (VNS), Rehabilitation, Targeted Plasticity Therapy

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Double blind, randomized placebo controlled, optional open-label extension design
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immediate Start Vagus Nerve Stimulation group
Arm Type
Experimental
Arm Description
The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
Arm Title
Delayed Start Vagus Nerve Stimulation group
Arm Type
Placebo Comparator
Arm Description
The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately 6 weeks during phase 1. For phase 2, all subjects will be provided the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately 6 weeks. Participants that elect to continue in the open-label extension will be assessed approximately 1 week after the conclusion of the additional 18 sessions of therapy.
Intervention Type
Device
Intervention Name(s)
Active Vagus Nerve Stimulation
Other Intervention Name(s)
VNS, vagus nerve stimulation, paired VNS
Intervention Description
Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
Intervention Type
Device
Intervention Name(s)
Placebo Vagus Nerve Stimulation
Other Intervention Name(s)
placebo, control
Intervention Description
During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
Primary Outcome Measure Information:
Title
Incidence of Adverse Events [Device Safety]
Description
Review of adverse events reported throughout the trial will be used to inform the potential risks associated with the ReStore system and provide a better understanding of risk/benefit analysis.
Time Frame
From Week 1 through study follow-up, approximately two years from the date of implant
Secondary Outcome Measure Information:
Title
Restore System Feasibility during Rehabilitation
Description
If stimulation delivery is successful during the active portion of therapy sessions then the system is feasible to use. The primary endpoint will be: greater than 50% of the valid attempts to stimulate are successful per the ReStore system log.
Time Frame
Weeks 7-12, Weeks 14-19
Title
Quantitative Force and Range of Motion Assessment
Description
This is a physical assessment of upper limb changes in force/torque as a result of VNS paired rehabilitation. The primary endpoints will be: 10% increase in finger pinch and flexion force following active VNS, 10% increase in wrist flexion and extension force following active VNS, and 10% increase in wrist pronation and supination force following active VNS. This will serve as an efficacy measurement to use as basis for estimate of sample size for a pivotal trial.
Time Frame
Week 1, 6, 13, 20
Title
Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP)
Description
Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) is a measure used for spinal cord injury patients. The measure includes five subsets of questions designed to quantitatively measure clinical upper limb impairment (Kalsi-Ryan et al., 2012). The primary endpoint will be: >4 point shift in GRASSP assessment following active VNS. This will serve as an efficacy measurement to use as basis for estimate of sample size for a pivotal trial.
Time Frame
Week 1, 6, 13, 20

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria In order to be eligible to participate in this study, an individual must meet all of the following criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Adult, aged 18-64 In good general health as evidenced by medical history and diagnosed with first time cervical spinal cord injury resulting in an ASIA grade B, C, or D, and level 1 or better motor function as described by the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). SCI caused by trauma that occurred ≥ 12 months prior to enrollment Meets all clinical criteria for the surgical VNS implantation as determined by the PI, surgeon, and anesthesiologist Must demonstrate some residual upper limb and hand movement in either arm Appropriate candidate for VNS implantation Willing and able to comply with the study protocol Exclusion Criteria An individual who meets any of the following criteria will be excluded from participation in this study: Spinal cord injuries by sharp objects, firearms, and non-traumatic or congenital causes, even if at different levels of the spinal cord Any evidence of recurrent laryngeal nerve injury (Evident during required laryngoscopy for all participants with Prior right-sided anterior cervical surgery- done prior to randomization) Excessive scar tissue marking implantation unsafe (evident at surgery) Concomitant clinically significant brain injuries Prior injury to vagus nerve Prior or current treatment with vagus nerve stimulation Participant receiving any therapy (medication or otherwise) that would interfere with VNS Pregnancy or lactation Clinical complications that hinder or contraindicate the surgical procedure Psychiatric disorders, psychosocial, and/or cognitive impairment that would interfere with study participation, as assessed by medical evaluation Abusive use of alcohol and/or illegal substances use Participation in other interventional clinical trial Participants with known immunodeficiency including participants who are receiving or have received chronic corticosteroids, immunosuppressants, immunostimulating agents or radiation therapy within 6 months Significant comorbidities or conditions associated with high risk for surgical or anesthetic survival (e.g. renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.). Active neoplastic disease. Participants with significant local circulatory problems, (e.g. thrombophlebitis and lymphedema). Participants with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator, including systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the participant unable to perform appropriate postoperative rehabilitation. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance. Aphasia and other cognitive deficits that make understanding the potential risks and benefits of the study impossible for participant. Inability to personally provide informed consent. A recent history of syncope A recent history of dysphagia Currently require, or are likely to require diathermy Significant respiratory issues that would interfere with participation Non-English speaking Patients who are acutely suicidal and/or have been admitted for a suicide attempt Incarceration or legal detention
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alvaro Carrera
Phone
469-831-5321
Email
alvaro.carrera@bswhealth.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Kilgard, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Rennaker, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Seth Hays, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jane Wigginton, MD
Organizational Affiliation
University of Texas Southwestern Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rita Hamilton, DO
Organizational Affiliation
Baylor Scott & White Institute for Rehabilitation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Foreman, MD FACS
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mark Powers, PhD
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Richard Naftalis, MD, FAANS, FACS
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
Facility Information:
Facility Name
Baylor University Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alvaro Carrera
Phone
469-831-5321
Email
alvaro.carrera@bswhealth.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24891012
Citation
Biering-Sorensen F, Bryden A, Curt A, Friden J, Harvey LA, Mulcahey MJ, Popovic MR, Prochazka A, Sinnott KA, Snoek G. International spinal cord injury upper extremity basic data set. Spinal Cord. 2014 Sep;52(9):652-7. doi: 10.1038/sc.2014.87. Epub 2014 Jun 3.
Results Reference
background
PubMed Identifier
16909143
Citation
Catz A, Itzkovich M, Tesio L, Biering-Sorensen F, Weeks C, Laramee MT, Craven BC, Tonack M, Hitzig SL, Glaser E, Zeilig G, Aito S, Scivoletto G, Mecci M, Chadwick RJ, El Masry WS, Osman A, Glass CA, Silva P, Soni BM, Gardner BP, Savic G, Bergstrom EM, Bluvshtein V, Ronen J. A multicenter international study on the Spinal Cord Independence Measure, version III: Rasch psychometric validation. Spinal Cord. 2007 Apr;45(4):275-91. doi: 10.1038/sj.sc.3101960. Epub 2006 Aug 15.
Results Reference
background
PubMed Identifier
15609737
Citation
Corson K, Gerrity MS, Dobscha SK. Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care. 2004 Nov;10(11 Pt 2):839-45.
Results Reference
background
PubMed Identifier
21228773
Citation
Engineer ND, Riley JR, Seale JD, Vrana WA, Shetake JA, Sudanagunta SP, Borland MS, Kilgard MP. Reversing pathological neural activity using targeted plasticity. Nature. 2011 Feb 3;470(7332):101-4. doi: 10.1038/nature09656. Epub 2011 Jan 12.
Results Reference
background
PubMed Identifier
24309259
Citation
Hays SA, Rennaker RL, Kilgard MP. Targeting plasticity with vagus nerve stimulation to treat neurological disease. Prog Brain Res. 2013;207:275-99. doi: 10.1016/B978-0-444-63327-9.00010-2.
Results Reference
background
PubMed Identifier
17852230
Citation
Itzkovich M, Gelernter I, Biering-Sorensen F, Weeks C, Laramee MT, Craven BC, Tonack M, Hitzig SL, Glaser E, Zeilig G, Aito S, Scivoletto G, Mecci M, Chadwick RJ, El Masry WS, Osman A, Glass CA, Silva P, Soni BM, Gardner BP, Savic G, Bergstrom EM, Bluvshtein V, Ronen J, Catz A. The Spinal Cord Independence Measure (SCIM) version III: reliability and validity in a multi-center international study. Disabil Rehabil. 2007 Dec 30;29(24):1926-33. doi: 10.1080/09638280601046302. Epub 2007 Mar 5.
Results Reference
background
PubMed Identifier
5788487
Citation
Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969 Jun;50(6):311-9. No abstract available.
Results Reference
background
PubMed Identifier
21568688
Citation
Kalsi-Ryan S, Beaton D, Curt A, Duff S, Popovic MR, Rudhe C, Fehlings MG, Verrier MC. The Graded Redefined Assessment of Strength Sensibility and Prehension: reliability and validity. J Neurotrauma. 2012 Mar 20;29(5):905-14. doi: 10.1089/neu.2010.1504. Epub 2011 Aug 12.
Results Reference
background
PubMed Identifier
22330108
Citation
Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, Johansen M, Jones L, Krassioukov A, Mulcahey MJ, Schmidt-Read M, Waring W. International standards for neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 2011 Nov;34(6):535-46. doi: 10.1179/204577211X13207446293695. No abstract available.
Results Reference
background
PubMed Identifier
11556941
Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
Results Reference
background
PubMed Identifier
24469147
Citation
Widerstrom-Noga E, Biering-Sorensen F, Bryce TN, Cardenas DD, Finnerup NB, Jensen MP, Richards JS, Siddall PJ. The International Spinal Cord Injury Pain Basic Data Set (version 2.0). Spinal Cord. 2014 Apr;52(4):282-6. doi: 10.1038/sc.2014.4. Epub 2014 Jan 28.
Results Reference
background
PubMed Identifier
6880820
Citation
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Results Reference
background

Learn more about this trial

Targeted Plasticity Therapy for Upper Limb Rehabilitation in Spinal Cord Injuries

We'll reach out to this number within 24 hrs